CHICAGO, June 22, 2011 /PRNewswire/ -- Amended 13D for RepliGen Corporation  was filed with the SEC by Mr. Ronald L. Chez, a private investor.
Mr. Ronald L. Chez is the President of Ronald L. Chez, Inc., and a private investor.
RepliGen Corporation is a biopharmaceutical company focused on building an integrated company by developing and marketing innovative drugs that deliver the benefits of protein therapies in the fields of neurology and gastroenterology. RepliGen has a core competency in the development and manufacturing of biologics products, which is the basis for its bioprocessing business and RepliGen has out-licensed certain biologics intellectual property, which provide ongoing sources of revenue. Corporate headquarters are located at 41 Seyon Street, Waltham, Massachusetts 02453.